Collegium Pharmaceutical, Inc (COLL) shareholders
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.95+0.14 (+0.56%)
Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
39M of 33M shares
Institutional holders
279
45 new, 29 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 11 sales
Net sold $4.38M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,997,827 | 15.60% | 13G (passive) amendment | Mar 31, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (7.40%), Israel A. Englander (7.40%) and 1 more | 2,400,985 | 7.40% | 13G (passive) amendment | Sep 30, 2026 |
| Eventide Asset Management, LLC Joint filing with Finny Kuruvilla, M.D. Ph. D. (5.90%), Robin C. John (5.90%) | 1,876,239 | 5.90% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC | 1,825,651 | 5.80% | 13G (passive) | Mar 31, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.60%), Millennium Group Management LLC (5.60%) and 1 more | 1,820,330 | 5.60% | 13G (passive) | Aug 17, 2026 |
| State Street Corporation | 1,772,243 | 5.40% | 13G (passive) | Sep 30, 2026 |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | 5.03% | 13G (passive) | Jun 30, 2026 |
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (5.06%) | 1,599,189 | 5.06% | 13G (passive) | Sep 8, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COLL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,441,202 | 16.71% | $196.97M | +307,175 | 0.00% |
| Jupiter Topco LLC | 2,147,072 | 6.60% | $77.74M | New | 0.03% |
| Invesco Ltd. | 1,882,499 | 5.78% | $68.15M | +290,590 | 0.01% |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | 5.02% | $59.11M | +133,197 | 0.16% |
| Principal Financial Group Inc | 1,632,360 | 5.01% | $59.09M | +337,332 | 0.03% |
| State Street Corp | 1,528,881 | 4.70% | $55.35M | +104,337 | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 1,405,567 | 4.32% | $50.88M | +39,635 | 0.02% |
| Vanguard Capital Management LLC | 1,381,261 | 4.24% | $50.00M | +47,269 | 0.00% |
| Renaissance Technologies LLC | 1,366,549 | 4.20% | $49.47M | −102,900 | 0.07% |
| Eventide Asset Management, LLC | 1,361,228 | 4.18% | $49.27M | −63,054 | 0.66% |
| Rubric Capital Management LP | 1,279,611 | 3.93% | $46.32M | – | 0.42% |
| Geode Capital Management, LLC | 890,886 | 2.74% | $32.26M | +71,446 | 0.00% |
| Dimensional Fund Advisors LP | 837,877 | 2.57% | $30.33M | +4,685 | 0.01% |
| Victory Capital Management Inc | 760,252 | 2.34% | $27.52M | +134,948 | 0.02% |
| Goldentree Asset Management LP | 744,889 | 2.29% | $26.92M | New | 1.56% |
| Vanguard Portfolio Management LLC | 740,081 | 2.27% | $26.79M | +59,700 | 0.00% |
| Millennium Management LLC | 736,925 | 2.26% | $26.68M | +376,099 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 621,920 | 1.91% | $22.51M | −81,608 | 0.01% |
| Assenagon Asset Management S.A. | 617,834 | 1.90% | $22.37M | +305,236 | 0.01% |
| Goldman Sachs Group Inc | 556,927 | 1.71% | $20.16M | −18,214 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 279 | 39M | 100.0% | 45 / 120 | 84 / 29 | 7M | 4M |
| Q1 2026 | 267 | 38M | 100.0% | 41 / 109 | 77 / 46 | 7M | 5M |
| Q4 2025 | 279 | 39M | 100.0% | 52 / 86 | 107 / 15 | 6M | 4M |
| Q3 2025 | 244 | 37M | 100.0% | 43 / 84 | 87 / 21 | 5M | 3M |
| Q2 2025 | 223 | 36M | 100.0% | 20 / 89 | 83 / 34 | 2M | 3M |
| Q1 2025 | 242 | 37M | 100.0% | 33 / 78 | 97 / 25 | 3M | 4M |
| Q4 2024 | 238 | 37M | 100.0% | 36 / 71 | 92 / 46 | 3M | 5M |
| Q3 2024 | 249 | 39M | 100.0% | 40 / 101 | 77 / 19 | 9M | 4M |
| Q2 2024 | 229 | 40M | 100.0% | 37 / 93 | 75 / 34 | 5M | 6M |
| Q1 2024 | 228 | 41M | 100.0% | 52 / 79 | 77 / 16 | 5M | 4M |
| Q4 2023 | 193 | 40M | 100.0% | 33 / 58 | 77 / 13 | 5M | 3M |
| Q3 2023 | 174 | 39M | 100.0% | 17 / 74 | 59 / 21 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
304 funds held COLL in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of COLL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,954,487 | 6.00% | $70.75M | 0.06% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 1,561,408 | 4.80% | $56.52M | 0.45% | Jun 30, 2026 |
| Eventide Gilead Fund | 1,344,376 | 4.13% | $48.67M | 1.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 977,957 | 3.00% | $35.40M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 856,942 | 2.63% | $31.02M | 0.04% | Jun 30, 2026 |
| SmallCap Fund | 641,300 | 1.97% | $22.70M | 1.09% | Jul 31, 2026 |
| MFS New Discovery Fund | 585,155 | 1.80% | $19.67M | 0.92% | May 31, 2026 |
| Invesco Main Street Small Cap Fund | 411,484 | 1.26% | $14.90M | 0.56% | Jun 30, 2026 |
| MFS New Discovery Value Fund | 396,902 | 1.22% | $13.34M | 0.54% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 369,871 | 1.14% | $13.39M | 0.01% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 365,632 | 1.12% | $12.94M | 2.74% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 359,376 | 1.10% | $12.72M | 0.04% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 319,959 | 0.98% | $10.75M | 0.04% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 303,980 | 0.93% | $11.00M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 296,717 | 0.91% | $10.74M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vikram Karnani | President and CEO, Director | 176,629 | 0.54% | Feb 12, 2026 |
| David Dieter | EVP & General Counsel | 68,231 | 0.21% | Apr 3, 2026 |
| Scott Dreyer | EVP & Chief Commercial Officer | 75,329 | 0.23% | Mar 5, 2026 |
| Thomas B. Smith | EVP and Chief Medical Officer | 85,312 | 0.26% | Feb 12, 2026 |
| Colleen Tupper | EVP & Chief Financial Officer | 147,282 | 0.45% | Feb 12, 2026 |
| Shirley R. Kuhlmann | EVP and General Counsel | 108,137 | 0.33% | Mar 6, 2025 |
| Gino Santini | Director | 112,483 | 0.35% | Jun 10, 2026 |
| John Gordon Freund | Director | 115,706 | 0.36% | May 20, 2026 |
| Donovan Michael Glancy | Director | 17,482 | 0.05% | May 18, 2026 |
| Nancy Lurker | Director | 26,758 | 0.08% | May 18, 2026 |
| Garen G. Bohlin | Director | 71,000 | 0.22% | May 18, 2026 |
| Carlos V. Paya | Director | 28,323 | 0.09% | May 18, 2026 |
| Rita J. Balice-Gordon | Director | 61,370 | 0.19% | May 18, 2026 |
| John A. Fallon | Director | 99,487 | 0.31% | Nov 14, 2025 |
| Michael Thomas Heffernan | Director | 213,371 | 0.66% | Feb 12, 2025 |
| Capital Management LP Rubric | 10% owner | 3,132,743 | 9.62% | Aug 15, 2025 |
| David Efraim Rosen | 10% owner | 3,157,743 | 9.70% | Aug 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gino Santini Director | Jun 8, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 112,483 |
| John Gordon Freund Director | May 18, 2026 | Sale | −20 | $34.05 | $681 | 83,952 |
| John Gordon Freund Director | May 15, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 88,099 |
| John Gordon Freund Director | May 15, 2026 | Sale | −4,127 | $34.54 | $142.55K | 83,972 |
| Gino Santini Director | May 14, 2026 | Award | +8,741 | – | – | 103,783 |
| Rita J. Balice-Gordon Director | May 14, 2026 | Award | +8,741 | – | – | 61,370 |
| John Gordon Freund Director | May 14, 2026 | Award | +8,741 | – | – | 79,399 |
| Carlos V. Paya Director | May 14, 2026 | Award | +8,741 | – | – | 28,323 |
| Nancy Lurker Director | May 14, 2026 | Award | +8,741 | – | – | 26,758 |
| Garen G. Bohlin Director | May 14, 2026 | Award | +8,741 | – | – | 71,000 |
| Donovan Michael Glancy Director | May 14, 2026 | Award | +17,482 | – | – | 17,482 |
| Nancy Lurker Director | May 13, 2026 | Sale | −4,500 | $35.97 | $161.87K | 18,017 |
| Garen G. Bohlin Director | May 11, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 70,959 |
| Garen G. Bohlin Director | May 11, 2026 | Sale | −8,700 | $37.18 | $323.47K | 62,259 |
| David Dieter EVP & General Counsel | Mar 18, 2026 | Sale(10b5-1 plan) | −13,976 | $34.92 | $488.04K | 77,071 |
| David Dieter EVP & General Counsel | Mar 17, 2026 | Tax withholding | −8,840 | $35.72 | $315.76K | 68,231 |
| David Dieter EVP & General Counsel | Mar 9, 2026 | Sale(10b5-1 plan) | −6,224 | $36.65 | $228.11K | 91,047 |
| Scott Dreyer EVP & Chief Commercial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −46,417 | $40.36 | $1.87M | 75,329 |
| Scott Dreyer EVP & Chief Commercial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −3,559 | $40.99 | $145.88K | 71,770 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Tax withholding | −2,781 | $46.75 | $130.01K | 97,271 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Award | +9,005 | – | – | 100,052 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Award | +22,194 | – | – | 91,047 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Award | +14,268 | – | – | 85,312 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Award | +22,774 | – | – | 108,086 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Tax withholding | −11,538 | $46.75 | $539.40K | 90,651 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Tax withholding | −5,897 | $46.75 | $275.68K | 102,189 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Award | +19,023 | – | – | 122,636 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Award | +30,702 | – | – | 153,338 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −9,977 | $46.75 | $466.42K | 143,361 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −21,615 | $46.75 | $1.01M | 121,746 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −26,679 | $46.75 | $1.25M | 147,282 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −11,861 | $46.75 | $554.50K | 173,961 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Award | +26,421 | – | – | 153,088 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Award | +32,734 | – | – | 185,822 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Award | +79,264 | – | – | 176,629 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Award | +32,531 | – | – | 209,160 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Tax withholding | −11,296 | $46.75 | $528.09K | 197,864 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Option exercise | +17,600 | $15.90 | $279.84K | 121,213 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −6,475 | $48.66 | $315.07K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −11,125 | $47.89 | $532.78K | 110,088 |
| Rita J. Balice-Gordon Director | Dec 5, 2025 | Sale | −3,650 | $47.03 | $171.66K | 52,629 |
| Vikram Karnani President and CEO, Director | Nov 12, 2025 | Tax withholding | −8,983 | $47.35 | $425.35K | 96,989 |
| John A. Fallon Director | Nov 12, 2025 | Option exercise | +19,853 | $9.33 | $185.23K | 99,487 |
| John A. Fallon Director | Nov 12, 2025 | Sale | −34,853 | $47.21 | $1.65M | 64,634 |
| John A. Fallon Director | Nov 12, 2025 | Option exercise | +15,000 | $16.49 | $247.35K | 79,634 |
| Colleen Tupper EVP & Chief Financial Officer | Nov 6, 2025 | Sale(10b5-1 plan) | −4,858 | $41.28 | $200.54K | 126,667 |
| Colleen Tupper EVP & Chief Financial Officer | Nov 6, 2025 | Sale(10b5-1 plan) | −25,142 | $40.38 | $1.02M | 131,525 |
| Thomas B. Smith EVP and Chief Medical Officer | Aug 29, 2025 | Sale | −17,478 | $38.42 | $671.50K | 70,264 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −16,389 | $38.21 | $626.22K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 18, 2025 | Option exercise | +16,389 | $21.34 | $349.74K | 120,002 |
| Gino Santini Director | Aug 15, 2025 | Sale | −5,405 | $37.19 | $201.01K | 95,042 |
| Gino Santini Director | Aug 15, 2025 | Option exercise | +15,000 | $13.45 | $201.75K | 100,447 |
| Capital Management LP Rubric 10% owner | Aug 13, 2025 | Sale | −25,000 | $37.85 | $946.25K | 3,132,743 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 13, 2025 | Sale(10b5-1 plan) | −4,861 | $38.03 | $184.86K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 13, 2025 | Option exercise | +4,861 | $21.34 | $103.73K | 108,474 |
| John Gordon Freund Director | Aug 8, 2025 | Sale | −11,659 | $34.36 | $400.60K | 23,129 |
| John Gordon Freund Director | Jun 9, 2025 | Sale | −6,601 | $30.62 | $202.12K | 70,658 |
| John Gordon Freund Director | Jun 9, 2025 | Option exercise | +15,000 | $13.45 | $201.75K | 77,259 |
| Nancy Lurker Director | May 15, 2025 | Award | +9,791 | – | – | 22,517 |
| Gino Santini Director | May 15, 2025 | Award | +9,791 | – | – | 85,447 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
16.68%
5M shares short
Days to cover
9.4
At 1M shares a day
Change since last report
-3.4%
From 5M shares
Short volume, 20 days
52.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Collegium Pharmaceutical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,325 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Scott Dreyer Former Officer | Sep 30, 2026 | 27,419 | $603.32K | Sep 30, 2026 | Restricted Stock Vesting |
| John A. Fallon Former Director | Jul 17, 2026 | 13,920 | $497.43K | Jul 17, 2026 | Stock Option Exercise |
| John A. Fallon Former Director | Jul 15, 2026 | 8,095 | $294.01K | Jul 15, 2026 | Stock Option Exercise |
| John Gordon Freund Director | May 18, 2026 | 30 | $1.02K | May 18, 2026 | Restricted Stock Vesting |
| John Gordon Freund Director | May 15, 2026 | 4,127 | $142.55K | May 15, 2026 | Option Granted - 06/09/2016 |
| Nancy Lurker Director | May 13, 2026 | 4,500 | $161.86K | May 13, 2026 | Restricted Stock Vesting |
| Garen G. Bohlin Director | May 11, 2026 | 8,700 | $323.49K | May 11, 2026 | Option Granted - 06/09/2016 |
| David Dieter Officer | Mar 18, 2026 | 13,976 | $488.10K | Mar 18, 2026 | Restricted Stock Vesting |
| David Dieter Officer | Mar 9, 2026 | 6,224 | $228.11K | Mar 9, 2026 | Restricted Stock Vesting |
| Scott Dreyer Officer | Mar 3, 2026 | 49,976 | $2.02M | Mar 3, 2026 | Restricted Stock Vesting |
| Rita J. Balice-Gordon DIRECTOR | Dec 17, 2025 | 3,650 | $171.67K | Dec 5, 2025 | VESTING OF RESTRICTED STOCK UNITS |
| Scott Dreyer Officer | Dec 8, 2025 | 17,600 | $847.86K | Dec 8, 2025 | Options Granted - 01/25/2019 |
| John A. Fallon Director | Nov 12, 2025 | 34,853 | $1.65M | Nov 12, 2025 | Option Granted - 06/09/2016 |
| Colleen Tupper Officer | Nov 6, 2025 | 30,000 | $1.22M | Nov 6, 2025 | Restricted Stock Vesting |
| Thomas B. Smith Officer | Aug 29, 2025 | 17,478 | $671.58K | Aug 29, 2025 | Vested RSUs |
See a number that looks wrong?